Last Update: Mar 13, 2024
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
ClinicalTrials.gov Identifier:
Novartis Reference Number:CABL001J12302
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

This study is a phase IIIb, multi-center, open-label, randomized study of oral asciminib 80 mg once daily (QD) versus nilotinib 300 mg twice daily (BID) in adult patients with newly diagnosed Ph+ CML-CP.

Participants will be randomized in the study in a 1:1 ratio to asciminib or nilotinib. No crossover of study treatment across arms will be allowed.

Participants will be treated until unacceptable toxicity, disease progression and/or at the discretion of the investigator or the participants. A safety follow up visit/call will be performed approximately 30 days after end of treatment visit. Participants who discontinue study treatment prematurely due to any reason, will be followed up for survival and progression (to Accelerated Phase (AP)/Blast Crisis (BC)) up until end of study.

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Phase 3
Recruiting
550
Nov 21, 2022
Mar 15, 2027
All
18 Years - (Adult, Older Adult)

Interventions

Drug

Asciminib

Asciminib 80 mg QD administered under fasting conditions.
Drug

Nilotinib

Nilotinib 300 mg BID administered under fasting conditions.

Eligibility Criteria

Inclusion Criteria:

Patients with CML-CP within 3 months of diagnosis.

Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of the Philadelphia chromosome

Documented chronic phase CML will meet all the below criteria Baccarani et al 2013:

< 15% blasts in peripheral blood and bone marrow,
< 30% blasts plus promyelocytes in peripheral blood and bone marrow,
< 20% basophils in the peripheral blood,
PLT count ≥ 100 x 10^9/L (≥ 100,000/mm3), except treatment induced thrombocytopenia
No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.
Evidence of typical BCR::ABL1 transcript [e14a2 and/or e13a2] which is amenable to standardized RQ-PCR quantification by the central laboratory assessment.
ECOG performance status of 0 or 1.

Adequate end organ function as defined by:

Total bilirubin (TBL) < 3 x ULN; patients with Gilbert's syndrome may only be included if TBL ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN,
CrCl ≥ 30 mL/min as calculated using Cockcroft-Gault formula, Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis.

Patients must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization:

Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min)**,
Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min),
Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with CrCl* ≥ 90 mL/min),

For patients with mild to moderate renal impairment (CrCl* ≥ 30 mL/min and <90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be within normal limits or corrected to within normal limits with supplements prior to randomization.

CrCl as calculated using Cockcroft-Gault formula. **Pseudohyperkaliemia in case of thrombocytosis is not an exclusion criterion.

Exclusion Criteria:

Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide.
Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).

Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:

History of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment.
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block).
QTcF ≥ 450 ms on the average of three serial baseline ECG (using the QTcF formula). If QTcF ≥ 450 ms and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTcF.
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
Inability to determine the QTcF interval.
Severe and/or uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia).
History of significant congenital or acquired bleeding disorder unrelated to cancer.
Major surgery within 4 weeks prior to study entry or patients who have not recovered from prior surgery.
History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively.
History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.
History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.
Known history of chronic Hepatitis B (HBV), or chronic Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) and Hepatitis B core antibody (HBc Ab/anti HBc) will be performed at screening. If anti-HBc is positive, HBV-DNA evaluation will be carried out at screening. A patient having positive HBV-DNA will not be enrolled in the study. Also, a patient with positive HBsAg will not be enrolled in the study. HCV Ab testing will also be performed at screening. For details on the criteria see Appendix 4.
History of Human Immunodeficiency Virus (HIV) unless well-controlled on a stable dose of anti-retroviral therapy at the time of screening.

Other protocol-defined Inclusion/exclusion criteria will apply.

Study Location

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1181ACH,Argentina

Novartis Investigative Site

Recruiting

Caba,Buenos Aires,C1221ADH,Argentina

Novartis Investigative Site

Recruiting

Buenos aires,C1039AAC,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,C1114AAN,Argentina

Novartis Investigative Site

Recruiting

Buenos Aires,C1425AUM,Argentina

Novartis Investigative Site

Recruiting

Plovdiv,4002,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1431,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1797,Bulgaria

Novartis Investigative Site

Recruiting

Varna,9010,Bulgaria

Novartis Investigative Site

Recruiting

Pleven,5800,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1413,Bulgaria

Novartis Investigative Site

Recruiting

Toronto,Ontario,M5G 2M9,Canada

Novartis Investigative Site

Recruiting

Plzen-Bory,30599,Czech Republic

Novartis Investigative Site

Recruiting

Praha 10,100 34,Czech Republic

Novartis Investigative Site

Recruiting

Brno Bohunice,Czech Republic,625 00,Czech Republic

Novartis Investigative Site

Recruiting

Praha 2,Czech Republic,128 20,Czech Republic

Novartis Investigative Site

Recruiting

Paris 10,75475,France

Novartis Investigative Site

Recruiting

Bordeaux,33076,France

Novartis Investigative Site

Recruiting

Lille,59037,France

Novartis Investigative Site

Recruiting

Poitiers,86000,France

Novartis Investigative Site

Recruiting

Vandoeuvre les Nancy cedex,54511,France

Novartis Investigative Site

Recruiting

Caen Cedex,14033,France

Novartis Investigative Site

Recruiting

Toulouse,31059,France

Novartis Investigative Site

Recruiting

Nantes Cedex 1,44093,France

Novartis Investigative Site

Recruiting

Strasbourg,67200,France

Novartis Investigative Site

Recruiting

Marseille,13273,France

Novartis Investigative Site

Recruiting

Nice,06202,France

Novartis Investigative Site

Recruiting

Lyon,69373,France

Novartis Investigative Site

Recruiting

Clermont Ferrand,63003,France

Novartis Investigative Site

Recruiting

Wuerzburg,97080,Germany

Novartis Investigative Site

Recruiting

Magdeburg,39104,Germany

Novartis Investigative Site

Recruiting

Halle S,06120,Germany

Novartis Investigative Site

Recruiting

Leipzig,04103,Germany

Novartis Investigative Site

Recruiting

Muenchen,80377,Germany

Novartis Investigative Site

Recruiting

Augsburg,86179,Germany

Novartis Investigative Site

Recruiting

Frankfurt,60590,Germany

Novartis Investigative Site

Recruiting

Mannheim,Baden Wuerttemberg,68305,Germany

Novartis Investigative Site

Recruiting

Ulm,89081,Germany

Novartis Investigative Site

Recruiting

Hamburg,20246,Germany

Novartis Investigative Site

Recruiting

Bad Saarow,15526,Germany

Novartis Investigative Site

Recruiting

Freiburg,79106,Germany

Novartis Investigative Site

Recruiting

Jena,07740,Germany

Novartis Investigative Site

Recruiting

Marburg,35039,Germany

Novartis Investigative Site

Recruiting

Bremen,28177,Germany

Novartis Investigative Site

Recruiting

Hannover,30161,Germany

Novartis Investigative Site

Recruiting

Dresden,Sachsen,01307,Germany

Novartis Investigative Site

Recruiting

Chemnitz,09113,Germany

Novartis Investigative Site

Recruiting

Bayreuth,95445,Germany

Novartis Investigative Site

Recruiting

Heidelberg,69120,Germany

Novartis Investigative Site

Recruiting

Luebeck,23538,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Erlangen,91054,Germany

Novartis Investigative Site

Recruiting

Velbert,North Rhine-Westphalia,42551,Germany

Novartis Investigative Site

Recruiting

Aachen,52074,Germany

Novartis Investigative Site

Recruiting

Bonn,53105,Germany

Novartis Investigative Site

Recruiting

Tuebingen,72076,Germany

Novartis Investigative Site

Recruiting

Paderborn,33098,Germany

Novartis Investigative Site

Recruiting

Regensburg,93049,Germany

Novartis Investigative Site

Recruiting

Muenchen,Bayern,81241,Germany

Novartis Investigative Site

Recruiting

Essen,45147,Germany

Novartis Investigative Site

Recruiting

Patras,265 00,Greece

Novartis Investigative Site

Recruiting

Athens,106 76,Greece

Novartis Investigative Site

Recruiting

Thessaloniki,GR,570 10,Greece

Novartis Investigative Site

Recruiting

Ioannina,GR,455 00,Greece

Novartis Investigative Site

Recruiting

Larissa,GR,411 10,Greece

Novartis Investigative Site

Recruiting

Athens,115 27,Greece

Novartis Investigative Site

Recruiting

Budapest,1085,Hungary

Novartis Investigative Site

Recruiting

Budapest,1097,Hungary

Novartis Investigative Site

Recruiting

Eger,3300,Hungary

Novartis Investigative Site

Recruiting

Rishikesh,Uttarakhand,249203,India

Novartis Investigative Site

Recruiting

Ahmedabad,Gujrat,380009,India

Novartis Investigative Site

Recruiting

Varanasi,Uttar Pradesh,221010,India

Novartis Investigative Site

Recruiting

New Delhi,110029,India

Novartis Investigative Site

Recruiting

Chennai,Tamilnadu,600036,India

Novartis Investigative Site

Recruiting

Torino,TO,10126,Italy

Novartis Investigative Site

Recruiting

Bari,BA,70124,Italy

Novartis Investigative Site

Recruiting

Meldola,FC,47014,Italy

Novartis Investigative Site

Recruiting

Pisa,PI,56126,Italy

Novartis Investigative Site

Recruiting

Milano,MI,20162,Italy

Novartis Investigative Site

Recruiting

Amman,11941,Jordan

Novartis Investigative Site

Recruiting

Uijeongbu si,Gyeonggi Do,11759,Korea, Republic of

Novartis Investigative Site

Recruiting

Bundang Gu,Gyeonggi Do,13620,Korea, Republic of

Novartis Investigative Site

Recruiting

Alor Setar,Kedah,05460,Malaysia

Novartis Investigative Site

Recruiting

Penang,10050,Malaysia

Novartis Investigative Site

Recruiting

Petaling Jaya,Selangor Darul Ehsan,46150,Malaysia

Novartis Investigative Site

Recruiting

Kuala Lumpur,59100,Malaysia

Novartis Investigative Site

Recruiting

Kuching,Sarawak,93586,Malaysia

Novartis Investigative Site

Recruiting

Dordrecht,3318AT,Netherlands

Novartis Investigative Site

Recruiting

Muscat,123,Oman

Novartis Investigative Site

Recruiting

Bucuresti,021494,Romania

Novartis Investigative Site

Recruiting

Cluj-Napoca,400124,Romania

Novartis Investigative Site

Recruiting

Craiova,200136,Romania

Novartis Investigative Site

Recruiting

Sibiu,550245,Romania

Novartis Investigative Site

Recruiting

Tg Mures,Mures,540136,Romania

Novartis Investigative Site

Recruiting

Bucharest,District 2,022328,Romania

Novartis Investigative Site

Recruiting

Bucharest,030 171,Romania

Novartis Investigative Site

Recruiting

Timisoara,300079,Romania

Novartis Investigative Site

Recruiting

Singapore,119228,Singapore

Novartis Investigative Site

Recruiting

Singapore,169608,Singapore

Novartis Investigative Site

Recruiting

Singapore,S308433,Singapore

Novartis Investigative Site

Recruiting

Bratislava,85107,Slovakia

Novartis Investigative Site

Recruiting

Kosice,Slovak Republic,040 66,Slovakia

Novartis Investigative Site

Recruiting

Soweto,Gauteng,2013,South Africa

Novartis Investigative Site

Recruiting

Pretoria,0044,South Africa

Novartis Investigative Site

Recruiting

Genève,1211,Switzerland

Novartis Investigative Site

Recruiting

Istanbul,TUR,34098,Turkey

Novartis Investigative Site

Recruiting

Izmir,35040,Turkey

Novartis Investigative Site

Recruiting

Ankara,06100,Turkey

Novartis Investigative Site

Recruiting

Abu Dhabi,United Arab Emirates

Novartis Investigative Site

Recruiting

London,SE5 9RS,United Kingdom

Novartis Investigative Site

Recruiting

London,W12 0HS,United Kingdom

Novartis Investigative Site

Recruiting

Glasgow,G12 0YN,United Kingdom

Novartis Investigative Site

Recruiting

Truro,Cornwall,TR1 3LJ,United Kingdom

Novartis Investigative Site

Recruiting

Gloucester,GL1 3NN,United Kingdom

Novartis Investigative Site

Recruiting

Gwent,NP9 2UB,United Kingdom

Texas Oncology P A .

Recruiting

Bedford,Virginia Butterworth email: [email protected] -- Andrew Jackson,76022 - Texas,United States

Hematology and Oncology Clinic .

Recruiting

Baton Rouge,Paige Pigee email: [email protected] -- Michael Castine III,70809 - Louisiana,United States

Oncology Hematology Care Inc .

Recruiting

Cincinnati,Zachary Beck email: [email protected] -- Kruti Patel,45242 - Ohio,United States

Virginia Oncology Associates VOA - Princess Anne

Recruiting

Norfolk,Emily Jones (757-368-0437) email: [email protected] -- Celeste Bremer,23502 - Virginia,United States

Illinois Cancer Care

Recruiting

Peoria,Heather Thulean (309-243-3661) email: [email protected] -- Srinivas Jujjavarapu,61615 - Illinois,United States

Regions Hospital Oncology Research Consortium

Recruiting

Saint Paul,Yan Ji,55101 - Minnesota,United States

Williamette Cancer Center

Recruiting

Eugene,Alexandra Chavez email: [email protected] -- Luke Fletcher,97401 - Oregon,United States

Lumi Research

Recruiting

Kingwood,Whitney Nwole (281-809-0676) email: [email protected] -- Saleha Sajid,77339 - Texas,United States

Rocky Mountain Cancer Centers USOR

Recruiting

Boulder,Lee Dimopoulos (303-385-2000) email: [email protected] -- David J Andorsky,80304 - Colorado,United States

Messino Cancer Centers

Recruiting

Asheville,Taylor McNeely email: [email protected] -- Andrew Beardsley,28806 - North Carolina,United States

Arizona Oncology Associates .

Recruiting

Phoenix,Alan Langerak,85016 - Arizona,United States

Sarah Cannon Research Institute HCA Healthcare Research Inst

Recruiting

Nashville,Vanesa Veletanlic (615-515-1900) email: [email protected] -- Stephen Strickland,37203 - Tennessee,United States

Minnesota Oncology Hematology P A Minnesota Oncology Hematology

Recruiting

Minneapolis,Brianna Lennox (612-884-6300) email: [email protected] -- Danielle Tippit,55404 - Minnesota,United States

Florida Cancer Specialists Dept of Oncology (2)

Recruiting

Fort Myers,Kelly Whitehead (+1 727 216 1143) email: [email protected] -- Adewale Alade Fawole,33901 - Florida,United States

Texas Oncology P A Midtown

Recruiting

Dallas,Shawnty Witham (512-421-4100) email: [email protected] -- Jason M Melear,75251 - Texas,United States

Florida Cancer Specialists Pan .

Recruiting

Tallahassee,Lindsey Murkerson (615-329-7482) email: [email protected] -- Jeffrey Bubis,32308 - Florida,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals